Medikamentenvergleiche
Semaglutide vs. Repaglinide
Semaglutide vs Repaglinide for T2D: GLP-1 agonist vs meglitinide. Compare A1c, weight loss, CV benefits vs postprandial control and hypo risk.
Für diese Seite sind keine Vergleichsdimensionen verfügbar.
Klinischer Kontext
This comparison is relevant when choosing oral agents for type 2 diabetes, especially oral GLP-1 (Rybelsus) versus a mealtime meglitinide in patients needing postprandial coverage.
Fazit
Semaglutide is generally preferred for broader metabolic and CV benefits, while Repaglinide suits flexible mealtime dosing with functioning beta cells.
Alle Medikamentenvergleiche